UWM Research Foundation Licenses a Novel Cancer Drug Compound to Systems Oncology

Article ID: 669123

Released: 8-Feb-2017 1:05 PM EST

Source Newsroom: University of Wisconsin-Milwaukee

Newswise — MILWAUKEE_ Arizona-based Systems Oncology has licensed a patented drug compound from the University of Wisconsin-Milwaukee Research Foundation. The compound employs a unique mechanism of action that has safely and effectively suppressed tumors in animal models. Specifically, the compound changes a transcription reprogram in tumor cells. Transcription is the process of turning specific genes on. Groups of genes can be turned on or off together as a transcriptional program that regulates a cell’s behavior.

Dr. Alexander Arnold, an associate professor of chemistry and biochemistry, discovered novel small molecules that can disrupt the interaction between the vitamin D receptor (VDR) and other proteins that regulate transcription. When VDR binds to the activated form of vitamin D, it drives a transcriptional program for proper cell growth and differentiation. Local degradation of the active form of vitamin D may lead to uncontrolled cancer growth, and malignant remodeling of the tumor microenvironment, which is the environment in and around the tumor. This makes tumors less likely to respond to cancer drugs and cancer immune-therapy.

“Initial studies suggest that new drug candidates that bind the VDR can be a safe and effective therapy for some difficult to treat cancers,” Arnold said. “By using these newly discovered molecules we can target the regulation of VDR genes.”

But VDR also is the “master regulator” of calcium in the body. Several new anti-cancer drugs in clinical trials are based on vitamin D, but they may disrupt the body’s vital levels of calcium over time. More importantly, cancer cells over-express proteins that inactivate the active form of vitamin D in the microenvironment of a tumor, reducing the efficacy of such therapies.

Arnold’s compounds alter the VDR’s action selectively, and block the local inactivation of vitamin D around the tumor microenvironment, without interfering with the systemic calcium regulation needed for normal health. Systems Oncology LLC is a machine learning-based biotechnology company that uses cognitive computing and multi-scalar systems modeling to mine massive datasets and uncover hidden therapeutic insights for cancer.

Dr. Spyro Mousses, the company’s CEO, said his team recognized the tremendous therapeutic opportunity in the VDR mechanism discovered by Arnold and can clinically position the cancer therapy for rapid approval. “Dr. Arnold and his team created a truly excellent small molecule compound. Our modeling work suggests that the compound’s unique mechanism of action has the potential to transform how we manage some of the toughest cancer types. We are excited to have the opportunity to work with pharmaceutical co-development partners to translate this important new agent into a breakthrough cancer therapy,” Mousses said. The UWM Research Foundation, a nonprofit corporation that provides research, entrepreneurship and innovation programs at UWM, has supported Arnold’s research and helped to commercialize it.

###

About Systems Oncology LLCSystems Oncology (SO) combines multi-scalar systems modeling with machine learning and Big Data to uncover breakthrough insights into cancer biology, and to expose novel therapeutic vulnerabilities. New scientific insights are then used by SO’s multidisciplinary team of cancer drug developers to better select, acquire, and develop truly innovative therapeutic agents. SO’s world-class team also has the experience and knowhow needed to intelligently translate scientific insights into smarter clinical development strategies and faster registration paths. Systems Oncology then partners with leading pharmaceutical partners to accelerate the co-development of breakthrough cancer treatments. Taken together, Systems Oncology represents a new model for translating scientific insights into innovative cancer therapies with unprecedented speed, scale, and precision.

About UWMRecognized as one of the nation’s 115 top research universities, UW-Milwaukee provides a world-class education to 26,000 students from 89 countries on a budget of $667 million. Its 14 schools and colleges include Wisconsin’s only schools of architecture, freshwater sciences and public health, and it is a leading educator of nurses and teachers. UW-Milwaukee partners with leading companies to conduct joint research, offer student internships and serve as an economic engine for southeastern Wisconsin. The Princeton Review named UW-Milwaukee a 2017 “Best Midwestern” university based on overall academic excellence and student reviews, as well as a top “Green College.”About UWM Research Foundation

About the UWM Research FoundationThe UWMRF is a nonprofit corporation that supports research, innovation and entrepreneurship at UWM through a variety of programs, including patenting and licensing. www.uwmresearchfoundation.org


Comment/Share

Chat now!